Company Overview of Genelux Corporation
Genelux Corporation, a biomedical company, develops diagnostic and therapeutic solutions for cancer and inflammatory diseases. Its product GL-ONC1 is a genetically stable oncolytic virus strain to locate, enter, colonize, and destroy cancer cells without harming healthy tissues or organs. Genelux Corporation was founded in 2001 and is headquartered in San Diego, California. The company has locations in Redlands, California; and Bernried, Germany.
3030 Bunker Hill Street
San Diego, CA 92109 5754
Founded in 2001
Key Executives for Genelux Corporation
Chief Executive Officer, President, Chief Compliance Officer and Director
Founder, Chairman Emeritus and Chief Scientific Advisor To The Chief Executive Officer
Chief Operating Officer, Director, Member of Scientific Advisory Board and Member of Clinical Advisory & Implementation Board
Chief Executive Officer of Genelux Europe and President of Genelux Europe
Compensation as of Fiscal Year 2015.
Genelux Corporation Key Developments
Genelux Corporation Announces Two Phase I Trials of GL-ONC1 in Head & Neck Cancer and Mesothelioma
May 27 15
Genelux Corporation announced that data from two Phase I trials evaluating its lead oncolytic virotherapy GL-ONC1 in head and neck cancer and malignant pleural mesothelioma demonstrate a favorable safety profile and support further investigation of the therapy in both indications. The results will be presented by lead investigators from Memorial Sloan Kettering Cancer Center and UC San Diego Moores Cancer Center at the upcoming 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29-June 2 in Chicago, IL. Data from the two Phase I trials are outlined. Abstract 6026 (Poster 349) Phase I trial of intravenous administration of attenuated vaccinia virus (GL-ONC1) with concurrent chemoradiotherapy (CRT) for locoregionally advanced head and neck carcinoma. The open-label, single-arm, dose-escalation study (NCT01584284) evaluated increasing doses of GL-ONC1 plus radiation and cisplatin in five cohorts of patients with late-stage disease (IVA or IVB), without reaching the maximum tolerated dose, indicating increased doses of GL-ONC1 may be feasible within the well-tolerated safety profile. Enrollment focused mostly on patients who have HPV-negative head and neck cancer, who are known to have poorer responses to standard of care than those with HPV-positive cancer.
Genelux Corporation Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 09:20 AM
Apr 11 15
Genelux Corporation Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 09:20 AM. Venue: Westin Grand Central Hotel, New York, New York, United States.
Genelux Announces Board Appointments
Jun 9 14
Genelux has appointed George Vandeman, long-time Amgen executive, and Thomas Zindrick, newly appointed Genelux President and CEO of Genelux, to the company's Board of Directors. Vandeman has also been named Vice Chairman and is the Board's fifth independent Director. Together, the appointments expand the Genelux Corp. Board to nine members.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|